Clinical Trial Update: Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a quadruple combination therapy (fruquintinib, nab-paclitaxel, iparomlimab, and tuvonralimab) for second-line, immunotherapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• Nab-paclitaxel (paclitaxel protein-bound)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Dai, Guanghai | Conditions: Gastric Cancer Adenocarcinoma Metastatic | Phase 2 | Status: RECRUITING